Calcitriol and its analogues enhance the antiproliferative activity of gefitinib in breast cancer cells

Journal of Steroid Biochemistry and Molecular Biology

Volumn 148, Issue , 2015, Pages 122-131

  Segovia Mendoza, Mariana ^a,b   Díaz, Lorenza ^a   González González, María Elena ^a   Martínez Reza, Isela ^a   García Quiroz, Janice ^a   Prado Garcia, Heriberto ^c   Ibarra Sánchez, María J ^a   Esparza López, José ^a   Larrea, Fernando ^a   García Becerra, Rocío ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

Author keywords

Breast cancer; Calcitriol; EGFR; Gefitinib; HER2; Vitamin D analogs

Indexed keywords

BIM PROTEIN; CALCIPOTRIOL; CALCITRIOL; CASPASE 3; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; SEOCALCITOL; VITAMIN D RECEPTOR; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; BCL-2-LIKE PROTEIN 11; MEMBRANE PROTEIN; MESSENGER RNA; ONCOPROTEIN; QUINAZOLINE DERIVATIVE; VITAMIN;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CELL CYCLE; DRUG EFFECTS; DRUG POTENTIATION; FEMALE; GENETICS; METABOLISM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BLOTTING, WESTERN; BREAST NEOPLASMS; CALCITRIOL; CASPASE 3; CELL CYCLE; CELL PROLIFERATION; DRUG SYNERGISM; FEMALE; HUMANS; MEMBRANE PROTEINS; PROTO-ONCOGENE PROTEINS; QUINAZOLINES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; VITAMINS;

EID: 84925535810     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2014.12.006     Document Type: Article

References (41)

1. N.E. Hynes, and H.A. Lane ERBB receptors and cancer: the complexity of targeted inhibitors Nat. Rev. Cancer 5 2005 341 354
2. Y. Yarden The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities Eur. J. Cancer 4 Suppl. 37 2001 S3 8
3. J.S. Ross, E.A. Slodkowska, W.F. Symmans, L. Pusztai, P.M. Ravdin, and G.N. Hortobagyi The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine Oncologist 14 2009 320 368
4. J. Baselga, and S.M. Swain Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 Nat. Rev. Cancer 9 2009 463 475
5. S.T. Lee-Hoeflich, L. Crocker, E. Yao, T. Pham, X. Munroe, K.P. Hoeflich, M.X. Sliwkowski, and H.M. Stern A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy Cancer Res. 68 2008 5878 5887
6. D. Graus-Porta, R.R. Beerli, J.M. Daly, and N.E. Hynes ErbB-2 the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling EMBO J. 16 1997 1647 1655
7. A.L. Harris, S. Nicholson, J.R. Sainsbury, J. Farndon, and C. Wright Epidermal growth factor receptors in breast cancer: association with early relapse and death, poor response to hormones and interactions with neu J. Steroid Biochem. 34 1989 123 131
8. A. Osaki, M. Toi, H. Yamada, H. Kawami, K. Kuroi, and T. Toge Prognostic significance of co-expression of c-erbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients Am. J. Surg. 164 1992 323 326
9. A. Harlozinska, J.K. Bar, R. Wenderski, and M. Bebenek Relationship between c-erbB-2 oncoprotein, epidermal growth factor receptor, and estrogen receptor expression in patients with ductal breast carcinoma. Association with tumor phenotypes In Vivo 10 1996 217 222
10. T.S. Mok, Y.L. Wu, S. Thongprasert, C.H. Yang, D.T. Chu, N. Saijo, P. Sunpaweravong, B. Han, B. Margono, Y. Ichinose, Y. Nishiwaki, Y. Ohe, J.J. Yang, B. Chewaskulyong, H. Jiang, E.L. Duffield, C.L. Watkins, A.A. Armour, and M. Fukuoka Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N. Engl. J. Med. 361 2009 947 957
11. J. Anido, P. Matar, J. Albanell, M. Guzman, F. Rojo, J. Arribas, S. Averbuch, and J. Baselga ZD1839 a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells Clin. Cancer Res. 9 2003 1274 1283
12. M. Campiglio, A. Locatelli, C. Olgiati, N. Normanno, G. Somenzi, L. Vigano, M. Fumagalli, S. Menard, and L. Gianni Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level J. Cell Physiol. 198 2004 259 268
13. S.L. Moulder, F.M. Yakes, S.K. Muthuswamy, R. Bianco, J.F. Simpson, and C.L. Arteaga Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo Cancer Res. 61 2001 8887 8895
14. M.M. Moasser, A. Basso, S.D. Averbuch, and N. Rosen The tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells Cancer Res. 61 2001 7184 7188
15. J. Krol, R.E. Francis, A. Albergaria, A. Sunters, A. Polychronis, R.C. Coombes, and E.W. Lam The transcription factor FOXO3a is a crucial cellular target of gefitinib (Iressa) in breast cancer cells Mol. Cancer Ther. 6 2007 3169 3179
16. D. Feldman, A.V. Krishnan, S. Swami, E. Giovannucci, and B.J. Feldman The role of vitamin D in reducing cancer risk and progression Nat. Rev. Cancer 14 2014 342 357
17. E.C. Janowsky, G.E. Lester, C.R. Weinberg, R.C. Millikan, J.M. Schildkraut, P.A. Garrett, and B.S. Hulka Association between low levels of 1,25-dihydroxyvitamin D and breast cancer risk Public Health Nutr. 2 1999 283 291
18. E.B. Mawer, J. Walls, A. Howell, M. Davies, W.A. Ratcliffe, and N.J. Bundred Serum 1,25-dihydroxyvitamin D may be related inversely to disease activity in breast cancer patients with bone metastases J. Clin. Endocrinol. Metab. 82 1997 118 122
19. U. Berger, R.A. McClelland, P. Wilson, G.L. Greene, M.R. Haussler, J.W. Pike, K. Colston, D. Easton, and R.C. Coombes Immunocytochemical determination of estrogen receptor, progesterone receptor, and 1,25-dihydroxyvitamin D3 receptor in breast cancer and relationship to prognosis Cancer Res. 51 1991 239 244
20. I.S. Mathiasen, U. Lademann, and M. Jaattela Apoptosis induced by vitamin D compounds in breast cancer cells is inhibited by Bcl-2 but does not involve known caspases or p53 Cancer Res. 59 1999 4848 4856
21. M. Simboli-Campbell, C.J. Narvaez, M. Tenniswood, and J. Welsh 1,25-Dihydroxyvitamin D3 induces morphological and biochemical markers of apoptosis in MCF-7 breast cancer cells J. Steroid Biochem. Mol. Biol. 58 1996 367 376
22. L. Lowe, C.M. Hansen, S. Senaratne, and K.W. Colston Mechanisms implicated in the growth regulatory effects of vitamin D compounds in breast cancer cells Recent Results Cancer Res. 164 2003 99 110
23. J. Garcia-Quiroz, R. Garcia-Becerra, D. Barrera, N. Santos, E. Avila, D. Ordaz-Rosado, M. Rivas-Suarez, A. Halhali, P. Rodriguez, A. Gamboa-Dominguez, H. Medina-Franco, J. Camacho, F. Larrea, and L. Diaz Astemizole synergizes calcitriol antiproliferative activity by inhibiting CYP24A1 and upregulating VDR: a novel approach for breast cancer therapy PLoS One 7 2012 e45063
24. N. Santos-Martinez, L. Diaz, D. Ordaz-Rosado, J. Garcia-Quiroz, D. Barrera, E. Avila, A. Halhali, H. Medina-Franco, M.J. Ibarra-Sanchez, J. Esparza-Lopez, J. Camacho, F. Larrea, and R. Garcia-Becerra Calcitriol restores antiestrogen responsiveness in estrogen receptor negative breast cancer cells: a potential new therapeutic approach BMC Cancer 14 2014 230
25. R. Vieth The mechanisms of vitamin D toxicity Bone Miner. 11 1990 267 272
26. M. Koga, J.A. Eisman, and R.L. Sutherland Regulation of epidermal growth factor receptor levels by 1,25-dihydroxyvitamin D3 in human breast cancer cells Cancer Res. 48 1988 2734 2739
27. Z. Shen, X. Zhang, J. Tang, R. Kasiappan, U. Jinwal, P. Li, S. Hann, S.V. Nicosia, J. Wu, and W. Bai The coupling of epidermal growth factor receptor down regulation by 1alpha, 25-dihydroxyvitamin D3 to the hormone-induced cell cycle arrest at the G1-S checkpoint in ovarian cancer cells Mol. Cell Endocrinol. 338 2011 58 67
28. J. Esparza-Lopez, H. Medina-Franco, E. Escobar-Arriaga, E. Leon-Rodriguez, A. Zentella-Dehesa, and M.J. Ibarra-Sanchez Doxorubicin induces atypical NF-kappaB activation through c-Abl kinase activity in breast cancer cells J. Cancer Res. Clin. Oncol. 139 2013 1625 1635
29. T.C. Chou Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies Pharmacol. Rev. 58 2006 621 681
30. K.K. Deeb, D.L. Trump, and C.S. Johnson Vitamin D signalling pathways in cancer: potential for anticancer therapeutics Nat. Rev. Cancer. 7 2007 684 700
31. D.L. Trump, K.K. Deeb, and C.S. Johnson Vitamin D: considerations in the continued development as an agent for cancer prevention and therapy Cancer J. 16 2010 1 9
32. S. Swami, A.V. Krishnan, and D. Feldman 1alpha, 25-dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells Clin. Cancer Res. 6 2000 3371 3379
33. Y. Ma, D.L. Trump, and C.S. Johnson Vitamin D in combination cancer treatment J. Cancer 1 2010 101 107
34. M.G. Fakih, D.L. Trump, J.R. Muindi, J.D. Black, R.J. Bernardi, P.J. Creaven, J. Schwartz, M.G. Brattain, A. Hutson, R. French, and C.S. Johnson A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors Clin. Cancer Res. 13 2007 1216 1223
35. J.R. Muindi, C.S. Johnson, D.L. Trump, R. Christy, K.L. Engler, and M.G. Fakih A phase I and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumors Cancer Chemother. Pharmacol. 65 2009 33 40
36. M.H. Cohen, G.A. Williams, R. Sridhara, G. Chen, W.D. McGuinn Jr., S. Morse, A. Rahman, C. Liang, R. Lostritto, A. Baird, and R. Pazdur United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets Clin. Cancer Res. 10 2004 1212 1218
37. T.M. Beer Development of weekly high-dose calcitriol based therapy for prostate cancer Urol. Oncol. 21 2003 399 405
38. K.R. McGaffin, and S.A. Chrysogelos Identification and characterization of a response element in the EGFR promoter that mediates transcriptional repression by 1,25-dihydroxyvitamin D3 in breast cancer cells J. Mol. Endocrinol. 35 2005 117 133
39. J.Y. Song, C.S. Kim, J.H. Lee, S.J. Jang, S.W. Lee, J.J. Hwang, C. Lim, G. Lee, J. Seo, S.Y. Cho, and J. Choi Dual inhibition of MEK1/2 and EGFR synergistically induces caspase-3-dependent apoptosis in EGFR inhibitor-resistant lung cancer cells via BIM upregulation Invest. New Drugs 31 2013 1458 1465
40. M.S. Cragg, J. Kuroda, H. Puthalakath, D.C. Huang, and A. Strasser Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics PLoS Med. 4 2007 1681 1689 Discussion 1690
41. M. Simboli-Campbell, C.J. Narvaez, K. van Weelden, M. Tenniswood, and J. Welsh Comparative effects of 1,25(OH) 2D3 and EB1089 on cell cycle kinetics and apoptosis in MCF-7 breast cancer cells Breast Cancer Res. Treat. 42 1997 31 41